USOC Announces Thirty-Day Disclosure of Doping Positives
COLORADO SPRINGS, COLO. (December 30, 2003) - - The United States Olympic
Committee (USOC) received notification from the U.S. Anti-Doping Agency
(USADA) 30 days ago that USADA’s Anti-Doping Review Board determined that
sufficient evidence of doping exists to proceed further in seven cases:
· Track and field athlete Chryste Gaines, 33, of Lithonia, Ga., tested
positive for modafinil at the USA Outdoor Track & Field Championships at
Stanford, Calif., on June 20, 2003.
· Track and field athlete Sandra Glover, 34, of Sugarland, Texas,
tested positive for modafinil at the USA Outdoor Track & Field
Championships at Stanford, Calif., on June 21, 2003.
· Track and field athlete John McEwen, 29, of Ashland, Ohio, tested
positive for modafinil and tetrahydrogestrinone (THG) at the USA Outdoor
Track & Field Championships at Stanford, Calif., on June 20, 2003.
· Track and field athlete Chris Phillips, 31, of Little Rock, Ark.,
tested positive for modafinil at the IAAF World Championships in Athletics
at Paris, France, on Aug. 30, 2003.
· Cyclist Adham Sbeih, 30, of Sacramento, Calif., tested positive for
erythropoietin (EPO) at the U.S. Cycling Federation (USCF) Elite Track
National Championships at Trexlertown, Pa., on Aug. 26, 2003.
· Track and field athlete Eric Thomas, 30, of Houston, Texas, tested
positive for modafinil at the USA Outdoor Track & Field Championships at
Stanford, Calif., on June 22, 2003.
· Track and field athlete Kelli White, 26, of Union City, Calif.,
tested positive for modafinil at the USA Outdoor Track & Field
Championships at Stanford, Calif., on June 20, 2003 and the IAAF World
Championships in Athletics at Paris, France, on Aug. 24, 2003.
Currently, all seven athletes are disputing their cases in the USADA
adjudication process. If a sanction is imposed, USADA will make the
announcement at a later date.
This announcement is made in accordance with the USOC’s published
Anti-Doping Policy, which was adopted in 2001 by the USOC Executive
Committee and requires this disclosure.
COLORADO SPRINGS, COLO. (December 30, 2003) - - The United States Olympic
Committee (USOC) received notification from the U.S. Anti-Doping Agency
(USADA) 30 days ago that USADA’s Anti-Doping Review Board determined that
sufficient evidence of doping exists to proceed further in seven cases:
· Track and field athlete Chryste Gaines, 33, of Lithonia, Ga., tested
positive for modafinil at the USA Outdoor Track & Field Championships at
Stanford, Calif., on June 20, 2003.
· Track and field athlete Sandra Glover, 34, of Sugarland, Texas,
tested positive for modafinil at the USA Outdoor Track & Field
Championships at Stanford, Calif., on June 21, 2003.
· Track and field athlete John McEwen, 29, of Ashland, Ohio, tested
positive for modafinil and tetrahydrogestrinone (THG) at the USA Outdoor
Track & Field Championships at Stanford, Calif., on June 20, 2003.
· Track and field athlete Chris Phillips, 31, of Little Rock, Ark.,
tested positive for modafinil at the IAAF World Championships in Athletics
at Paris, France, on Aug. 30, 2003.
· Cyclist Adham Sbeih, 30, of Sacramento, Calif., tested positive for
erythropoietin (EPO) at the U.S. Cycling Federation (USCF) Elite Track
National Championships at Trexlertown, Pa., on Aug. 26, 2003.
· Track and field athlete Eric Thomas, 30, of Houston, Texas, tested
positive for modafinil at the USA Outdoor Track & Field Championships at
Stanford, Calif., on June 22, 2003.
· Track and field athlete Kelli White, 26, of Union City, Calif.,
tested positive for modafinil at the USA Outdoor Track & Field
Championships at Stanford, Calif., on June 20, 2003 and the IAAF World
Championships in Athletics at Paris, France, on Aug. 24, 2003.
Currently, all seven athletes are disputing their cases in the USADA
adjudication process. If a sanction is imposed, USADA will make the
announcement at a later date.
This announcement is made in accordance with the USOC’s published
Anti-Doping Policy, which was adopted in 2001 by the USOC Executive
Committee and requires this disclosure.
Comment